Allo CART-19 Protocol

Status Terminated

Clinical Trial Summary

The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).

Clinical Trial Description

The investigators propose an open label, single center, pilot study to evaluate the safety and tolerability, and persistence of donor lymphocytes engineered to express a chimeric antigen receptor targeting CD19 which is linked to the CD3:4-1BB signaling chains in patients with CD19+ acute lymphoblastic leukemia (ALL). Upon enrollment, donors will undergo leukapheresis and patients will undergo an optional bone marrow/lymph node biopsy approximately four weeks prior to dosing. Between dosing and treatment, patients may undergo an additional chemotherapy treatment depending upon their disease. At dosing, patients will receive redirected donor lymphocytes targeted against CD19 (allo-CART-19 cells). The cell dose will be given as a split infusion over three days to enhance the ability to manage any infusion related toxicity. Patients will be monitored weekly for four weeks. At the end of four weeks, patients will undergo a second leukapheresis and second optional bone marrow/lymph node biopsy. At this point the patient will also undergo restaging. Observation and monitoring of patients will continue on a monthly basis until week 24 post dosing. Annual follow-up for lentiviral vector safety will be carried out for 15 years in accordance with FDA guidelines for retroviral vectors. Ten subjects will be targeted for this study, with an expected rate of drop out of 30% due to disease progression between enrollment and week four post dosing. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT01551043
Study type	Interventional
Source	University of Pennsylvania
Contact
Status	Terminated
Phase	Phase 1
Start date	September 2010
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03755414` - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	Phase 1
Withdrawn	`NCT05170828` - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	Phase 1
Recruiting	`NCT02892695` - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT01430390` - In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies	Phase 1
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00098033` - Investigation of Clofarabine in Acute Leukemias	Phase 2
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Completed	`NCT01930162` - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant	Phase 2
Completed	`NCT02581007` - Reduced Intensity Conditioning Transplant Using Haploidentical Donors	Phase 2
Terminated	`NCT01745913` - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies	Phase 2
Completed	`NCT03263637` - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies	Phase 1
Withdrawn	`NCT05201183` - A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT02819583` - CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma	Phase 1/Phase 2
Completed	`NCT00990587` - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy	Phase 1
Completed	`NCT00854646` - Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)	Phase 1
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Completed	`NCT00773149` - Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia	Phase 1/Phase 2
Recruiting	`NCT00271063` - Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia	Phase 1/Phase 2
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A
Completed	`NCT01965171` - Transfusional Iron Overload Among Leukemia Survivors	N/A